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Nuggehally R SrinivasDear Editor-in-Chief:
I read with interest a recently published article in your
esteemed journal by Lavasani et al., entitled “Study of
the pharmacokinetic changes of Tramadol in diabetic
rats” [1]. Lavasani et al., have evaluated the influence of
full-blown diabetes on the pharmacokinetic disposition
of tramadol using a rat model of diabetes mellitus in-
duced by streptozotocin (DMIS) [1]. Since tramadol has
been independently confirmed to have glucose lowering
potential in DMIS [2] and as well being investigated for
its role in alleviating pain in diabetic neuropathy [3,4],
this pharmacokinetic investigation in DMIS was time ap-
propriate. The design of the study also incorporated the
assessment of the role of hepatic function via a perfused
liver protocol [1]. The measurements of key circulating
metabolites [M1, M2 and M5] along with tramadol pro-
vided the necessary data required for the assessment of
the role of diabetes on the disposition of tramadol [1].
The results of this investigation unequivocally con-
firmed that the exposure of tramadol increased substan-
tially (approximately 4-fold) in diabetic rats with an
identical 4-fold reduction in the oral clearance [1]. Also,
the elimination rate constant for tramadol was reduced
by about 1.5 fold in diabetic rats [1]. In terms of metabo-
lites of tramadol, with the exception of M5 which
showed similar exposure in diabetic vs control rats, the
exposure of both M1 and M2 were about 1.42 to 1.76
fold greater in diabetic rats [1]. The perfused rat liver ex-
periment suggested that both M1 and M5 were being
formed in relatively higher amounts in diabetes rats vs
control rats. Interestingly, the metabolite to parent ratio
computation of diabetes rats vs control rats suggested
that diabetes rats had a lower ratio in spite of higherCorrespondence: srini.suramus@yahoo.com
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reproduction in any medium, provided the orturnover of metabolites by DMIS rat liver vs control rat
liver [1]. The authors have provided interesting views to
explain the observed findings of tramadol disposition in
the diabetes rats that included lower volume of distribu-
tion and protein binding to account for higher tramadol
exposure and possible CYP induction for the increased
M1 level [1].
The intent of this note is to provide additional clues to
further tease out the observed findings of tramadol dis-
position in diabetes rats. Although shift in volume of
distribution can alter exposure, perhaps, the decreased
total body clearance is the key driver to explain the ex-
posure increase for both tramadol and the metabolite
M1. The disposition of tramadol is governed by efficient
hepatic clearance and renal excretion of both the parent
and the major oxidative metabolites (inclusive of M1)
[5]. However, in diabetes rats the renal handling system
is severely handicapped [6,7] and therefore, impaired
renal excretion of tramadol and M1 can lead to in-
creased systemic exposure. It appeared that impaired
renal elimination of tramadol in DMIS rat model may
explain the increased bioavailability observed in diabetes
rats. The impaired renal elimination would also explain
the time dependent increased build-up of the tramadol ex-
posure in diabetes rats relative to control rats (Figure one;
Lavasani et al.). However, unlike the parent, the effect of
renal impairment on M1 appeared to have been more pro-
nounced post 1 h after dosing (Figure one; Lavasani et al.)
because there is a lag time for the hepatic formation of the
metabolite. Nevertheless, renal impairment appeared to be
an important contributor for the increased exposure of
M1 in diabetes rats.
In conclusion, the interesting work of Lavasani et al.,
has thrown some new light on the importance of well-
planned experiments to tease out the variables that ac-
count for pharmacokinetic disposition of tramadol inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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dosing of tramadol in diabetes rats vs control rats will
help in further elucidating the proposed mechanisms to
explain the altered pharmacokinetic disposition of
tramadol in diabetes rats [1]. However, it is strongly
recommended that urinary excretion rate and renal
clearance is also measured in this planned work to un-
equivocally establish the relationship of renal impair-
ment on the disposition of tramadol and its metabolites
in diabetes rats. Since tramadol is also excreted un-
changed in humans along with the active M1 metabolite
[8,9], the planned work is relevant to get dosing guid-
ance of tramadol in patients.
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